All News

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.

GSK secures exclusive rights to EMP-012, a promising treatment for COPD, enhancing its respiratory pipeline and addressing unmet medical needs.

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), offering adults with moderately to severely active ulcerative colitis a more convenient dosing option that maintains proven efficacy and long-term remission outcomes.

Investments surge in the pharmaceutical sector as companies like Zag Bio and Hemab Therapeutics advance innovative treatments for rare diseases.

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening events in adults with pulmonary arterial hypertension.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the impact on the various middle-men involved in drug-pricing.

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.

Organon faces leadership changes as CEO Kevin Ali resigns amid an investigation into improper sales practices involving Nexplanon.

Novartis acquires Avidity Biosciences to enhance its RNA therapeutics pipeline, targeting rare neuromuscular diseases with innovative therapies.

The group says that willpower alone won’t help most people.

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.

Lynkuet, a hormone-free therapeutic option for hot flashes associated with menopause, is expected to be available in the United States in November 2025.

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new funding momentum across rare disease R&D, and Eli Lilly’s definitive agreement to acquire Aderum Biotechnologies.

GSK's Blenrep gains FDA approval, offering new hope for multiple myeloma patients with improved survival rates and community access.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

The model imagines a new future in which traditional pharmacy distribution and access channels are bypassed.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.

In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and why clinical trial site satisfaction is becoming a key competitive differentiator for sponsors and CROs.

Pharma investments surge as companies like Summit Therapeutics and Elevara Medicines secure funding to advance innovative drug development and clinical trials.

The acquisition brings together two leaders in mRNA innovation, strengthening BioNTech’s oncology strategy and expanding its R&D and commercialization capabilities.

The decision impacts hopes for preventing congenital infections, although the company is continuing other research initiatives.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.

Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.